Business Wire

Joe Kiani Provides Keynote at the 5th Annual Global Ministerial Summit on Patient Safety

Share

In a keynote address at the Fifth Global Ministerial Summit on Patient Safety, Joe Kiani, founder of the Patient Safety Movement Foundation (PSMF), called for hospitals around the world to show greater transparency in reporting medical errors and preventable deaths. He also stressed the importance of aligned incentives, so providers are paid on quality of care rather than quantity and the adoption of Actionable Evidence-Based Practices addressing the known causes of harm.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230227005765/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Joe Kiani Provides Keynote at the 5th Annual Global Ministerial Summit on Patient Safety (Photo: Business Wire)

“We need not just access to healthcare, it has to be safe, it has to be dignified,” said Kiani. “To get there, we have to create self-governing actions. If we can agree on the medical errors that can be prevented through evidence-based practices, those then can be tracked by every hospital. And they could report every year, every quarter, on their website publicly, the number of harms they have for each of those errors.”

Transparency, Kiani argued, is critical because publicly revealing data on preventable medical errors helps to accelerate the pace of change.

In countries where healthcare is at least partially subsidized by the government, Kiani suggested introducing major financial incentives for hospitals to be more transparent and active in patient safety by implementing evidence-based practices for preventing errors.

“In my country, half of the care is paid for by the Government. Medicare and Medicaid pays for more than half the care in every hospital,” he said. “So therefore, they could mandate that to get that reimbursement, they want transparency, and that they will tie their performance to the payment. So if hospitals have zero medical errors, zero preventable deaths, they don't have to do anything. But if someone is harmed, and those evidence-based practices were not in place, they should not get paid. This becomes a way that every board of directors of every hospital will expect their management to implement evidence-based practices.”

As an example of how this can work, Kiani cited his time on the board of directors of Children's Hospital of Orange County (CHOC), California. “When I began at CHOC, I was happy to see they were looking at quality,” he said. “They were looking at medical errors, but they were comparing themselves to their colleagues, and if they were lower in error rate than others, that was considered a job well done. And I challenged them that shouldn't the goal be zero? To their credit, they accepted the challenge, and they went one step further, they tied the bonuses of the faculty to zero. Something incredible occurred at the next meeting, we went from hoping for zero, to planning for zero.”

“I want you all to take action out of kindness!” concluded Joe Kiani.

The Global Ministerial Summit on Patient Safety is an annual event that brings together ministers, high-level representatives, and experts from around the world. This year’s summit was hosted by President Alain Berset and the distinguished speakers included; Tedros Adhanom Ghebreyesus, Director-General, World Health Organization; Professor Didier Pittet, Professor of Medicine at the University of Geneva; Dr. Anthony Staines, Patient Safety Program Director of Vaud Hospital Federation in Switzerland; Professor Dr. Phil Lauren Clark, Professor of Implementation Science in Health Care; and Professor Sir Liam Donaldson, WHO Patient Safety Envoy.

This year the Patient Safety Movement Foundation will hold its 10th Annual World Patient Safety, Science & Technology Summit on June 1st and 2nd in Newport Beach, California.

ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION

In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP is available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 13:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 11:53:00 EET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release

Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye